Pharmacokinetics of N-acetylcysteine are altered in patients with chronic liver disease
The threshold plasma paracetamol concentration at which N-acetylcysteine (NAC) treatment is recommended to treat paracetamol poisoning in a patient with induced liver enzymens (for example, with chronic liver disease or taking anticonvulsant drugs) is 50% lower than in a patient without induces liver enzymes. More patients with chronic liver disease might therefore be expected to be exposed to NAC treatment than previously. In addition, there is increasing use of NAC in patients with chronic liver disease for multiorgan failure or hepatorenal syndrome. Little is known of NAC's pharmacokinetics properties in patiens with cirrhosis.